PTGS2 and ulcerative colitis: ALA, co- and post-treatment in mice with ulcerative colitis, not only prevents the transcription of COX-2, but also significantly reduces various inflammatory markers, such as myeloperoxidase, IL-17, IL-6, and TNF-α in the colon [145].